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pathological stage (P < 0.001), higher grade (P < 0.001), 
lymph node metastasis (P = 0.006), lymphovascu-
lar invasion (P < 0.001), concomitant carcinoma in situ 
(P < 0.001), multifocality (P = 0.004), tumor necrosis 
(P = 0.020) and sessile architecture (P < 0.001). Within a 
median follow-up of 30 months (interquartile range 15–57), 
171 patients (25.4 %) experienced disease recurrence and 
150 (21.9 %) died from UTUC. In univariable analyses, 
decreased E-cadherin expression was significantly associ-
ated with worse recurrence-free survival (P < 0.001) and 
cancer-specific survival CSS (P = 0.006); however, in mul-
tivariable analyses, it was not (P = 0.74 and 0.84, respec-
tively). The lack of independent prognostic value of E-cad-
herin remained true in all subgroup analyses.
Abstract 
Purpose  To assess the role of E-cadherin as prognostic 
biomarker in upper tract urothelial carcinoma (UTUC) in a 
large multi-institutional cohort of patients.
Methods  Immunohistochemistry technique was used to 
evaluate E-cadherin expression in 678 patients with unilat-
eral, sporadic UTUC treated with RNU. E-cadherin expres-
sion was considered decreased if 10 % or more cells had 
decreased expression (<90 %).
Results Decreased E-cadherin expression was observed in 
353 patients (52.1 %) and was associated with advanced 
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Conclusion In UTUC patients treated with RNU, 
decreased E-cadherin expression is associated with features 
of biologically and clinically aggressive disease and worse 
outcome in univariable, but not multivariable, analyses. If 
E-cadherin’s association with factors of advanced disease is 
confirmed on UTUC biopsy specimens, it could be used to 
help in the clinical decision-making regarding kidney-spar-
ing approaches and/or neo-adjuvant chemotherapy.
Keywords E-cadherin · Urothelium · Carcinoma · 
Recurrence · Prognosis · Survival · Prediction
Abbreviations
UTUC  Upper tract urothelial carcinoma
RFS  Recurrence-free survival
CSS  Cancer-specific survival
RNU  Radical nephroureterectomy
UCB  Urothelial carcinoma of the bladder
EMT  Epithelial–mesenchymal transition
LVI  Lymphovascular invasion
CI  Confidence interval
HR  Hazard ratio
Introduction
 Upper tract urothelial carcinoma (UTUC) is a rare disease, 
accounting for 5–10 % of all urothelial carcinomas [1]. In 
the last two decades, management of UTUC has improved 
but still remains challenging. Radical nephroureterectomy 
(RNU) remains the standard treatment for non-metastatic 
disease [1, 2]. However, kidney-sparing approaches are 
now considered for low-risk UTUC, and conversely, 
regional lymphadenectomy and perioperative chemother-
apy are discussed in addition to RNU for high-risk UTUC 
[1, 2]. Current concerns lay in the identification of the 
patients who may benefit from these treatments. Recent 
evidence suggests that carcinogenetic mechanisms in 
UTUC are different from urothelial carcinoma of the blad-
der (UCB) [2–4]. Therefore, molecular alterations from one 
setting may not be extrapolated in the other. In this regard, 
specific validation of biomarkers in UTUC is mandatory to 
develop predictive tools that could allow accurate clinical 
decision-making in the management of UTUC patients.
Decreased expression of the membrane-associated gly-
coprotein E-cadherin has been established as a feature of 
epithelial–mesenchymal transition (EMT) in epithelial 
malignancies [5–7]. In normal cells, E-cadherins’ cytoplas-
mic domain binds with subtypes β or γ of the catenin pro-
teins, which in turn secure attachment to the actin micro-
filament, thus ensuring cytoskeleton integrity and stable 
cellular adhesion [8]. Loss of cellular adhesion is a tipping 
point in tumor progression resulting in poorly differentiated 
and invasive tumors [7, 8]. E-cadherin has been shown to be 
an independent prognostic factor in UCB [3, 9]. In UTUC, 
single-center studies with small cohorts have investigated 
the role of E-cadherin expression with conflicting results 
[10–15]. We hypothesized that E-cadherin expression in 
RNU specimens was associated with features of biologi-
cally and clinically aggressive UTUC, thereby potentially 
helping in the clinical decision-making of UTUC patients. 
To assess this hypothesis, we tested the association of 
E-cadherin with pathologic characteristics and prognosis 
in a large multi-institutional cohort of patients treated by 
RNU for UTUC.
Materials and methods
Patient selection
This was a retrospective, institutional review board-
approved study involving seven institutions from the inter-
national UTUC collaboration [16]. The initial study cohort 
comprised 753 patients who underwent RNU for UTUC 
(Ta–T4 N0–1 M0) between March 1990 and May 2008. 
Exclusion criteria included neo-adjuvant chemotherapy/
radiotherapy and follow-up <3 months, resulting in a final 
cohort of 678 patients.
Data collection, pathological evaluation 
and immunochemistry
A computerized database was used to collect patient and 
tumor characteristics. All surgical specimens were pro-
cessed according to standard pathological procedures. 
Original pathology slides were centrally collected and ana-
lyzed by genitourinary pathologists blinded to clinical out-
come. Pathological stage was determined according to the 
2002 tumor, node and metastasis (TNM) staging system, 
and the pathological grading using the 1998 WHO/ISUP 
consensus classification. The tumors were architecturally 
defined as papillary or sessile [17]. The presence of tumor 
cells within an endothelium-lined space without underly-
ing muscular walls was defined as lymphovascular invasion 
(LVI) [18]. Multifocal tumor [19], carcinoma in situ and 
tumor necrosis [20] were confirmed in every slide.
E-cadherin staining was performed on formalin-fixed 
tissue microarray slides constructed for the study in a single 
laboratory, as described previously [9]. Antigen retrieval 
was performed and the primary anti-E-CD monoclonal 
mouse antibody (Transduction Labs, dilution 1:25 in block-
ing solution) was incubated for 1 h. Secondary antibody 
(Vector Labs) was applied at a dilution of 1:400. Reactivity 
was visualized with an avidin–biotin complex immunoper-
oxidase system using diamino benzidine as the chromogen 
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and methyl green and alcian blue as the counterstain. Posi-
tive controls included bladder and prostate tissue known to 
possess 100 % preserved E-cadherin expression (external 
control) and normal urothelium (internal control) included 
in cancer specimens. Negative controls were serial sections 
processed without incubation in primary antibody. Areas 
of urothelial tumor were classified as normal (90–100 % 
cells with preserved cell border staining resembling mem-
branous staining of normal controls) and abnormal, which 
included negative (0–10 % positive tumor cells) and various 
degrees of heterogeneous decreased expression (11–89 % 
positive tumor cells) (Fig. 1). Multiple sections from the 
same patient were evaluated to minimize the effect of the 
staining technique on interpretation. The negative and the 
heterogeneously staining tumors were considered together 
in statistical calculations based on the premise that the neg-
ative areas of the heterogeneous tumors would define the 
biological behavior of the tumor as a whole [9, 21].
Management and follow‑up
All patients underwent standard RNU [1]. Additionally, a 
regional lymphadenectomy was performed in 155 patients 
(22.9 %) and 68 patients (10 %) received adjuvant chemo-
therapy. Postoperative follow-up was generally performed 
every 3 months the first year after surgery, every 6 months in 
the second year and annually thereafter. Relapse was defined 
by local recurrence or distant metastasis. Cause of death was 
determined by chart review or death certificate [22].
Statistical analyses
Outcomes included recurrence-free survival (RFS) and 
cancer-specific survival (CSS). Chi-square test was used 
to assess decreased E-cadherin expression with categori-
cal variables. Differences in continuous variables were 
analyzed using Kruskal–Wallis tests. The Kaplan–Meier 
method was used to estimate RFS and CSS; log-rank tests 
were applied for pairwise comparison of survival. Univari-
able and multivariable Cox regression models addressed 
associations of RFS and CSS with potential prognostic 
factors. We performed subgroup analyses in patients with 
pTa–pT4 high-grade disease, pTa–pT2 N0/Nx, pT1–pT3 
N0/Nx, pT3/pT4 N0/Nx, pTa–pT4 pN0 and pTa–pT4 pN1 
disease. All P values were two-sided, and statistical signif-
icance was defined as P < 0.05. Statistical analyses were 
performed using Stata 11.0 statistical software (StataCorp., 
College Station, TX, USA).
Results
Descriptive characteristics and association 
with pathology
Decreased E-cadherin expression was observed in 353 
patients (52.1 %). There was a significant association 
between decreased E-cadherin expression and pathological 
adverse features such as advanced pathological tumor stage 
Fig. 1  E-cadherin immunohis-
tochemical staining of upper 
tract urothelial carcinoma: 
a normal expression (range 
90–100 %), b heterogenous 
expression (range 11–89 %) 
and c absent expression (range 
0–10 %)
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(P < 0.001), high pathological tumor grade (P < 0.001), 
lymph node metastases (P = 0.006), LVI (P < 0.001), 
concomitant carcinoma in situ (P < 0.001), multifocality 
(P = 0.004), tumor necrosis (P = 0.020) and sessile archi-
tecture (P < 0.001) (Table 1).
Association of decreased E‑cadherin expression 
with cancer recurrence and cancer‑specific survival
The median follow-up time was 30 months (15–57). Within 
this period, 171 patients (25.4 %) experienced disease 
recurrence and 150 (21.9 %) died from UTUC. In univari-
able analyses, decreased E-cadherin expression was associ-
ated with a higher probability of disease recurrence (log-
rank test P < 0.001, HR 1.69, 95 % CI 1.23–2.30) (Fig. 2a) 
and cancer-specific mortality (log-rank test P = 0.006, 
HR 1.57, 95 % CI 1.13–2.19) (Fig. 2b). Table 2 summa-
rizes the Cox regression analyses. In multivariable analy-
ses, decreased E-cadherin expression was not associated 
independently with either RFS (HR 1.06, P = 0.74) or CSS 
(HR 0.96, P = 0.84) (Table 2). 
Further univariable analyses in subgroups of patients 
revealed that decreased E-cadherin expression was asso-
ciated with worse outcomes in patients with pTa–pT4 M0 
high-grade tumors (HR 1.55, P < 0.011) and pTa–pT2 pN0/
Nx M0 tumors (HR 2.20, P < 0.038) regarding RFS and 
in patients with pTa–pT4 M0 high-grade tumors (HR 1.50, 
P < 0.025) regarding CSS. However, in these subgroups, 
the prognostic value of E-cadherin did not retain statistical 
significance when adjusted for the effects of standard clin-
icopathological features.
Discussion
In this study, we assessed the clinical significance of a 
decreased E-cadherin expression in an international cohort 
of 678 UTUC patients treated with RNU. We found that 
decreased E-cadherin expression in tumor cells is associ-
ated with adverse clinicopathological features and worse 
outcomes.
Half of the patients in this cohort presented with 
decreased expression of E-cadherin in the tumor. This was 
within the range previously reported in UCB patients (31–
77 %) [8, 9] but lower than that reported in UTUC patients 
(68–71 %) [10, 11]. This could be due to our lower propor-
tion of high stage tumors compared to the two other studies 
(50 vs. 54 and 61 %), as well as methodological differences 
in scoring, staining protocols, choice of antibody and/or 
antigen retrieval.
Patients with decreased E-cadherin were most likely to 
harbor tumors with features of biologically aggressive dis-
ease. This association is in line with the biological role of 
E-cadherin, as a calcium-dependent glycoprotein essen-
tial to epithelial tissue integrity. Loss of cellular adhesion 
results in the detachment of cancerous cells from the pri-
mary lesion, promoting invasiveness [23]. In carcinoma 
in situ of the bladder, for example, loss of E-cadherin 
expression predicts RFS, disease progression and CSS 
[21]. Similar results were reported in various UCB studies 
Table 1  Association of decreased E-cadherin expression with clin-
icopathological characteristics in 678 patients treated with radical 
nephroureterectomy for upper tract urothelial carcinoma
All patients Normal 
E-cadherin
Decreased 
E-cadherin
P
Total, n (%) 678 325 (47.9) 353 (52.1)
Age (years) 0.19
 Median 
(IQR)
69 (63–76) 69 (62–76) 70 (63–77)
Gender, n (%) 0.78
 Male 380 (56.1) 184 (56.6) 196 (55.5)
 Female 298 (43.9) 141 (43.4) 157 (44.5)
Tumor stage, n (%) <0.001
 pTa 121 (17.8) 82 (25.2) 39 (11.1)
 pT1 208 (30.7) 98 (30.1) 110 (31.2)
 pT2 123 (18.1) 60 (18.5) 63 (17.8)
 pT3 193 (28.5) 74 (22.8) 119 (33.7)
 pT4 33 (4.9) 11 (3.4) 22 (6.2)
Grade, n (%) <0.001
 Low 174 (25.6) 114 (35.1) 60 (17.0)
 High 504 (74.3) 211 (64.9) 293 (83.0)
Lymph node status, n (%) 0.006
 pNx 523 (77.2) 261 (80.3) 262 (74.2)
 pN0 108 (15.9) 52 (16) 56 (15.9)
 pN1 47 (6.9) 12 (3.7) 35 (9.9)
Lymphovascular invasion, n (%) <0.001
 Yes 135 (19.9) 26 (8.0) 109 (30.9)
 No 543 (80.1) 299 (92.0) 244 (69.1)
Concomitant carcinoma in situ, n (%) <0.001
 Yes 128 (18.9) 41 (12.6) 87 (24.7)
 No 550 (81.1) 284 (87.4) 266 (75.3)
Multifocality, n (%) 0.004
 Yes 145 (21.4) 54 (16.6) 91 (25.8)
 No 533 (78.6) 271 (83.4) 262 (74.2)
Necrosis, n (%) 0.020
 Yes 81 (11.9) 29 (8.9) 52 (14.7)
 No 597 (88.1) 296 (91.1) 301 (85.3)
Architecture, n (%) <0.001
 Papillary 558 (82.3) 293 (90.1) 265 (75.1)
 Sessile 120 (17.7) 32 (9.9) 88 (24.9)
Location 0.70
 Kidney 478 (70.5) 232 (71.4) 246 (69.7)
 Ureter 200 (29.5) 93 (28.6) 107 (30.3)
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[8, 9, 24–27] and one UTUC study [10]: loss of E-cadherin 
immunoreactivity strongly correlated with advanced stage 
and high-grade tumors.
We further evaluated the relevance of E-cadherin as 
a biomarker to predict outcomes after RNU. The role of 
E-cadherin expression as a prognostic factor in urothe-
lial carcinoma was supported by previous studies mainly 
focusing on UCB [8, 9, 24–27]. Our results confirm that 
decreased E-cadherin expression is indeed associated with a 
higher probability of disease recurrence and cancer-specific 
Fig. 2  Kaplan–Meier estimates 
of disease-free survival (a) and 
cancer-specific survival (b) 
according to the expression 
of E-cadherin in 678 patients 
treated with radical nephro-
ureterectomy for upper tract 
urothelial carcinoma
 World J Urol
1 3
mortality in UTUC. However, when adjusted for the effects 
of established prognostic factors in multivariable analy-
ses, E-cadherin expression lost its independent prognostic 
value and, therefore, may have only limited value in clini-
cal practice. Previous studies that addressed the relation-
ship between E-cadherin and outcomes in UTUC led to 
conflicting results. Fromont et al. [14] showed, in a cohort 
of 62 UTUC patients, that decreased E-cadherin expression 
was an independent prognostic factor for disease-free and 
overall survival. Conversely, most of the studies published 
thereafter with larger cohorts failed to demonstrate inde-
pendent association between E-cadherin expression and 
disease recurrence after RNU [10–13].
Consistent with the literature [10–13], we found, in our 
subgroup analysis that, E-cadherin failed to demonstrate 
any independent prognostic value, outlining its strong asso-
ciation with other established pathological prognostic fac-
tors. We found a significant association between E-cadherin 
expression and adverse clinicopathological features such 
as advanced pathological tumor stage, high pathological 
tumor grade, lymph node metastases, LVI, concomitant 
carcinoma in situ, multifocality, tumor necrosis and ses-
sile architecture. All these factors have been independently 
associated with worse outcome in UTUC [1, 2, 19, 20, 
28–30].
The biological and clinical roles of the E-cadherin-
related pathways in urothelial carcinomas are yet to be 
understood. Indeed, the regulation of E-cadherin is linked 
to many different biomarkers [2, 3]. Some of them have 
been already assessed in UTUC. Among them, Snail, a 
transcription factor is thought to repress the transcription of 
E-cadherin by binding to elements found in the E-cadherin 
promoter [12]. An increased Snail expression has been 
reported as an independent prognostic predictor of recur-
rence-free and CSS [12]. During EMT, it is thought that 
transcriptional regulation results in suppression of epithe-
lial markers and gain of mesenchymal markers [7, 12]. This 
process recognized in different types of cancer including 
bladder cancer [31, 32] and UTUC [11] has been observed 
between epithelial E-cadherin and mesenchymal N-cad-
herin and has been termed the “cadherin switch.” The novel 
genotype results in an alteration of normal tissue architec-
ture and high-grade, invasive tumors. To our knowledge, 
only one study by Muramaki et al. [11] addressed the role 
of N-cadherin expression in UTUC: In this study includ-
ing 59 patients, N-cadherin expression was an independent 
prognostic factor of intra- and extra-vesical recurrence after 
RNU. Combining several biomarkers may help character-
ize the different pathways involved in tumor aggressiveness 
and create a prediction algorithm that would improve prog-
nostication, clinical outcome and thus patient survival [33]. 
At this time the ideal combination of biomarkers remains 
unfortunately elusive. From the bladder cancer literature 
and some preliminary upper urinary tract literature, cell 
cycle markers (p53, pRB, p21, p27 and cyclins), apoptosis 
markers (Fas, caspase-3, Bcl-2 and survivin) and prolifera-
tion markers (Ki67) may be used for a combined approach 
[34]. Snail expression, N-cadherin expression, AKT 
Table 2  Multivariable Cox 
regression analyses predicting 
disease recurrence and cancer-
specific mortality of 678 
patients treated with radical 
nephroureterectomy for upper 
tract urothelial carcinoma
CI confidence interval, CIS carcinoma in situ, HR hazard ratio
Disease-free survival Cancer-specific survival
HR 95 % CI P value HR 95 % CI P value
Male gender 0.76 0.56–1.04 0.085 0.78 0.56–1.08 0.13
Age 1.02 0.99–1.03 0.052 1.03 1.01–1.04 0.006
Pathological stage Ref. Ref.
 Ta
 T1 1.80 0.76–4.28 0.184 1.48 0.57–3.80 0.42
 T2 3.58 1.52–8.44 0.003 3.49 1.40–8.73 0.008
 T3 7.31 3.21–16.65 <0.001 6.29 2.58–15.31 <0.001
 T4 32.98 12.81–84.87 <0.001 25.16 9.11–69.53 <0.001
Pathological high grade 1.38 0.82–2.32 0.23 1.59 0.89–2.82 0.12
Lymphovascular invasion 1.14 0.80–1.64 0.47 1.31 0.89–1.92 0.16
Concomitant CIS 1.52 1.03–2.23 0.035 1.06 0.69–1.63 0.78
Architecture 1.27 0.86–1.86 0.23 1.35 0.89–2.06 0.15
Necrosis 0.46 0.29–0.75 0.002 0.51 0.30–0.85 0.009
Multifocality 1.44 1.01–2.056 0.045 1.78 1.22–2.58 0.003
Kidney location 1.17 0.86–1.60 0.32 1.26 0.90–1.76 0.18
Lymph node metastasis 2.40 1.57–3.66 <0.001 2.28 1.46–3.55 <0.001
E-cadherin decreased expression 1.06 0.76–1.48 0.74 0.96 0.68–1.38 0.84
World J Urol 
1 3
pathway, β- or γ-catenins and matrix metalloproteinases are 
molecular markers associated with EMT that could be ana-
lyzed in a combined approach with E-cadherin expression.
We acknowledge that our study has some limitations. 
First and foremost are those related to its retrospective 
nature and the immunohistochemical technique. Indeed, 
this latter technique may be associated with a lack of repro-
ducibility related to the choice of antibodies, the speci-
men handling procedures, technical demands and scoring 
protocols. However, tissue microarray with staining proto-
cols and automated scoring systems based on bright field 
microscopy imaging coupled with advanced color detection 
software were used to overcome these common limitations. 
Finally, decreased expression of E-cadherin was defined 
according to a standard cutoff used in UCB and use of new 
thresholds may have led to different conclusions.
Conclusion
Decreased E-cadherin expression is associated with adverse 
clinicopathological UTUC features and worse outcomes in 
univariable analyses. E-cadherin expression is, however, 
not an independent prognostic factor when adjusted for the 
effects of established prognostic factors, limiting its use in 
clinical decision-making regarding prognosis after RNU. If 
E-cadherin’s association with factors of advanced disease is 
confirmed on UTUC biopsy specimens, it could be used to 
help in the clinical decision-making regarding kidney-spar-
ing approaches and/or neo-adjuvant chemotherapy.
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